News

Local cytokine release syndrome (L-CRS) is a potentially underrecognized complication of CAR T-cell therapy for blood cancer that can appear as cervical angioedema, or swelling in the deeper layers of tissue in the neck or throat, a study suggests. The swelling may occur after a bodywide inflammatory response has…

A six-month dosing regimen of Argo Biopharma‘s long-acting investigational therapy BW-20805 reduced monthly attacks in people with hereditary angioedema (HAE) by up to 99%. That’s according to new data from an ongoing open-label Phase 2 clinical trial (NCT06846398) testing the therapy in up to 25 adults, ages…

While there is a connection between angioedema and the use of angiotensin-converting enzyme inhibitors (ACEIs), a class of medications commonly used to manage cardiovascular problems, certain people with the condition can safely use ACEIs. That’s according to a Dutch study that examined primary care for people with angioedema…

Injectable on-demand treatments for children with hereditary angioedema (HAE) are often associated with anxiety, pain, treatment delays, and high use of emergency healthcare services, highlighting the need for a simpler treatment option, according to data from Kalvista Pharmaceuticals, the company that markets Ekterly (sebetralstat), an oral on-demand…

Long-term preventive treatment for hereditary angioedema (HAE) was associated with fewer swelling attacks requiring emergency or inpatient care, but many patients still struggle to remain on treatment and continue to experience a substantial disease burden, a claims-based real-world U.S. study reports. Among nearly 500 people who started preventive, or…

Researchers for the first time have developed separate liver cell lines, each derived from people with hereditary angioedema (HAE), that accurately replicate the molecular and cellular processes underlying the condition. “These models not only exhibit key molecular features of HAE but also provide a versatile platform for mechanistic studies…

Note: This story was updated May 26, 2026, to correct the time until symptom relief and the two formulations being investigated. Deucrictibant began relieving symptoms within a median of 1.28 hours. Developer Pharvaris is testing both immediate-release capsules and extended-release tablets. Pharvaris plans to soon submit an application to…

People with hereditary angioedema (HAE) who learn to accept and manage their disease, rather than constantly fighting or fearing it, often experience better mental well-being and a fuller, more active life, according to a survey study from the U.K. “Approaches aimed at fostering acceptance may offer a valuable means…

Patients with hereditary angioedema (HAE) should ideally receive on-demand treatment within one hour of their first symptoms, according to an international panel of 19 specialists. However, the experts warned that several obstacles, ranging from the difficulty in recognizing early symptoms to the physical burden of using needles, often…

Biocryst Pharmaceuticals is once again partnering with Neopharmed Gentili — now, with an Irish affiliate of the Italian pharmaceutical company — this time for marketing rights in Europe to navenibart, the still-experimental treatment Biocryst is developing to prevent attacks of hereditary angioedema (HAE) Under the terms of a new…